SynthesisFrontiers in oncology2025

Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies.

Yunke Zang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.